KBC Group NV Sells 99,972 Shares of Enovis Corporation (NYSE:ENOV)

KBC Group NV trimmed its position in Enovis Corporation (NYSE:ENOV - Free Report) by 97.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,587 shares of the company's stock after selling 99,972 shares during the period. KBC Group NV's holdings in Enovis were worth $99,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after buying an additional 75,348 shares during the period. Royce & Associates LP increased its holdings in Enovis by 2.8% in the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after acquiring an additional 66,891 shares during the last quarter. River Road Asset Management LLC increased its holdings in Enovis by 3.8% in the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock worth $54,339,000 after acquiring an additional 45,762 shares during the last quarter. Boston Partners increased its holdings in Enovis by 27.1% in the 4th quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after acquiring an additional 223,816 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Enovis by 25.0% in the 4th quarter. Royal Bank of Canada now owns 707,361 shares of the company's stock worth $31,038,000 after acquiring an additional 141,517 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ENOV shares. JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Needham & Company LLC decreased their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group reduced their target price on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $58.00.

Enovis Stock Down 1.8%

NYSE:ENOV opened at $33.03 on Tuesday. The firm's 50-day moving average price is $32.96 and its 200-day moving average price is $37.84. The company has a market capitalization of $1.89 billion, a PE ratio of -2.37 and a beta of 1.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32. Enovis Corporation has a 1-year low of $28.83 and a 1-year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The company had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. Enovis's revenue for the quarter was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.50 EPS. On average, equities analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.